AR125818A1 - Inhibidores de nlrp3 - Google Patents
Inhibidores de nlrp3Info
- Publication number
- AR125818A1 AR125818A1 ARP220101225A ARP220101225A AR125818A1 AR 125818 A1 AR125818 A1 AR 125818A1 AR P220101225 A ARP220101225 A AR P220101225A AR P220101225 A ARP220101225 A AR P220101225A AR 125818 A1 AR125818 A1 AR 125818A1
- Authority
- AR
- Argentina
- Prior art keywords
- halo
- alkyl
- cycloalkyl
- haloalkyl
- optionally substituted
- Prior art date
Links
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 title abstract 3
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 8
- 150000001875 compounds Chemical class 0.000 abstract 6
- 125000001188 haloalkyl group Chemical group 0.000 abstract 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 4
- 208000035475 disorder Diseases 0.000 abstract 4
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- HCMJWOGOISXSDL-UHFFFAOYSA-N (2-isothiocyanato-1-phenylethyl)benzene Chemical compound C=1C=CC=CC=1C(CN=C=S)C1=CC=CC=C1 HCMJWOGOISXSDL-UHFFFAOYSA-N 0.000 abstract 1
- -1 -OH Chemical group 0.000 abstract 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000002825 nitriles Chemical class 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Reivindicación 1: Compuestos de fórmula (1) en donde R¹ es H, acetilo, SF₅, halo, alquilo, haloalquilo, haloalcoxi o nitrilo; R⁵ es H; o R¹ y R⁵, y los átomos a los que están unidos, forman o un anillo de heterociclo de 4 - 6 miembros que comprende un único heteroátomo de O opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente de halo o alquilo, o bien R¹ y R⁵, y los átomos a los que están unidos, forman un anillo de cicloalquilo de 3 - 6 miembros opcionalmente sustituido con 1 a 2 sustituyentes seleccionados independientemente de halo o alquilo; R² es H, halo, alquilo, haloalquilo, cicloalquilo o cicloalquilalquilo, en donde cicloalquilo o cicloalquilalquilo está opcionalmente sustituido con halo; R³ es H, alquilo, haloalquilo, cicloalquilo o cicloalquilalquilo, en donde cicloalquilo o cicloalquilalquilo está opcionalmente sustituido con halo; Z es -O- o -NH-; R⁴ es un anillo de heterociclo opcionalmente sustituido con 1 a 3 sustituyentes seleccionados independientemente de halo, alquilo, haloalquilo, hidroxialquilo, -OH, oxo, -CO₂H, cicloalquilalquilo o cicloalquilo opcionalmente sustituido con halo; o R⁴ es un cicloalquilo opcionalmente sustituido con 1 a 3 sustituyentes seleccionados independientemente de alquilo, halo, haloalquilo y -OH; o R⁴ es arilalquilo o heteroarilalquilo, en donde arilalquilo o heteroarilalquilo tiene de 1 a 3 sustituyentes seleccionados independientemente de alquilo, halo, haloalquilo y -OH; y sales farmacéuticamente aceptables. Reivindicación 23: Un proceso para preparar un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 22, que comprende la reacción de un compuesto de fórmula (2) con un compuesto de fórmula (3), en donde R³ y R⁴ son como se definieron anteriormente. Reivindicación 25: Un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 22 para su uso en el tratamiento o prevención de una enfermedad, trastorno o afección, en donde la enfermedad, trastorno o afección responde a la inhibición de NLRP3. Reivindicación 27: El uso de un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 22 para el tratamiento o profilaxis de una enfermedad, trastorno o afección, en donde la enfermedad, trastorno o afección responde a la inhibición de NLRP3.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21173452 | 2021-05-12 | ||
| EP21209447 | 2021-11-22 | ||
| EP21215859 | 2021-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125818A1 true AR125818A1 (es) | 2023-08-16 |
Family
ID=81941106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101225A AR125818A1 (es) | 2021-05-12 | 2022-05-10 | Inhibidores de nlrp3 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20240208928A1 (es) |
| EP (2) | EP4337652B1 (es) |
| JP (1) | JP2024517917A (es) |
| KR (1) | KR20240007152A (es) |
| AR (1) | AR125818A1 (es) |
| AU (1) | AU2022275300A1 (es) |
| BR (1) | BR112023023527A2 (es) |
| CA (1) | CA3214626A1 (es) |
| CL (1) | CL2023003312A1 (es) |
| CO (1) | CO2023016204A2 (es) |
| CR (1) | CR20230529A (es) |
| DK (1) | DK4337652T3 (es) |
| ES (1) | ES3031704T3 (es) |
| FI (1) | FI4337652T3 (es) |
| HR (1) | HRP20250632T1 (es) |
| HU (1) | HUE071498T2 (es) |
| IL (1) | IL307188A (es) |
| LT (1) | LT4337652T (es) |
| MA (1) | MA64323B1 (es) |
| MX (1) | MX2023012907A (es) |
| PE (1) | PE20240126A1 (es) |
| PL (1) | PL4337652T3 (es) |
| RS (1) | RS66893B1 (es) |
| SI (1) | SI4337652T1 (es) |
| TW (1) | TW202311245A (es) |
| WO (1) | WO2022238347A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| AU2023205375A1 (en) * | 2022-01-07 | 2024-07-18 | Transthera Sciences (Nanjing) , Inc. | Nlrp3 inflammasome inhibitor and uses thereof |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| IL320499A (en) * | 2022-11-04 | 2025-06-01 | Transthera Sciences Nanjing Inc | Nlrp3 inflammasome inhibitor and use thereof |
| CR20250215A (es) * | 2022-12-07 | 2025-06-26 | Hoffmann La Roche | Compuestos novedosos como moduladores de la inhibición de nlrp3 |
| AU2024211236A1 (en) * | 2023-01-27 | 2025-08-14 | Mwyngil Therapeutics, Inc. | Inhibitors of nlrp3 |
| WO2024193541A1 (en) * | 2023-03-20 | 2024-09-26 | Insilico Medicine Ip Limited | Nlrp3 inflammasome inhibitors and uses thereof |
| WO2024193703A1 (zh) | 2023-03-23 | 2024-09-26 | 成都赜灵生物医药科技有限公司 | 三嗪类化合物及其用途 |
| AU2024280075A1 (en) | 2023-06-02 | 2025-12-11 | Merck Sharp & Dohme Llc | 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3 |
| CN121368590A (zh) | 2023-06-29 | 2026-01-20 | 豪夫迈·罗氏有限公司 | 作为nlrp3抑制剂的三嗪衍生物 |
| WO2025026882A1 (en) | 2023-07-28 | 2025-02-06 | F. Hoffmann-La Roche Ag | Novel compounds |
| WO2025059069A1 (en) * | 2023-09-12 | 2025-03-20 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
-
2022
- 2022-05-10 JP JP2023569634A patent/JP2024517917A/ja active Pending
- 2022-05-10 KR KR1020237038678A patent/KR20240007152A/ko active Pending
- 2022-05-10 WO PCT/EP2022/062525 patent/WO2022238347A1/en not_active Ceased
- 2022-05-10 BR BR112023023527A patent/BR112023023527A2/pt unknown
- 2022-05-10 ES ES22728228T patent/ES3031704T3/es active Active
- 2022-05-10 SI SI202230138T patent/SI4337652T1/sl unknown
- 2022-05-10 EP EP22728228.2A patent/EP4337652B1/en active Active
- 2022-05-10 IL IL307188A patent/IL307188A/en unknown
- 2022-05-10 RS RS20250561A patent/RS66893B1/sr unknown
- 2022-05-10 AR ARP220101225A patent/AR125818A1/es unknown
- 2022-05-10 HR HRP20250632TT patent/HRP20250632T1/hr unknown
- 2022-05-10 PL PL22728228.2T patent/PL4337652T3/pl unknown
- 2022-05-10 PE PE2023002971A patent/PE20240126A1/es unknown
- 2022-05-10 MX MX2023012907A patent/MX2023012907A/es unknown
- 2022-05-10 EP EP25167922.1A patent/EP4609865A3/en active Pending
- 2022-05-10 CR CR20230529A patent/CR20230529A/es unknown
- 2022-05-10 LT LTEPPCT/EP2022/062525T patent/LT4337652T/lt unknown
- 2022-05-10 AU AU2022275300A patent/AU2022275300A1/en active Pending
- 2022-05-10 MA MA64323A patent/MA64323B1/fr unknown
- 2022-05-10 DK DK22728228.2T patent/DK4337652T3/da active
- 2022-05-10 CA CA3214626A patent/CA3214626A1/en active Pending
- 2022-05-10 FI FIEP22728228.2T patent/FI4337652T3/fi active
- 2022-05-10 HU HUE22728228A patent/HUE071498T2/hu unknown
- 2022-05-11 TW TW111117580A patent/TW202311245A/zh unknown
-
2023
- 2023-11-07 CL CL2023003312A patent/CL2023003312A1/es unknown
- 2023-11-10 US US18/506,492 patent/US20240208928A1/en active Pending
- 2023-11-29 CO CONC2023/0016204A patent/CO2023016204A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE071498T2 (hu) | 2025-09-28 |
| CA3214626A1 (en) | 2022-11-17 |
| TW202311245A (zh) | 2023-03-16 |
| US20240208928A1 (en) | 2024-06-27 |
| EP4609865A2 (en) | 2025-09-03 |
| AU2022275300A1 (en) | 2023-09-21 |
| BR112023023527A2 (pt) | 2024-01-30 |
| EP4337652B1 (en) | 2025-04-09 |
| SI4337652T1 (sl) | 2025-07-31 |
| PE20240126A1 (es) | 2024-01-22 |
| DK4337652T3 (da) | 2025-06-10 |
| JP2024517917A (ja) | 2024-04-23 |
| EP4337652A1 (en) | 2024-03-20 |
| CL2023003312A1 (es) | 2024-06-21 |
| MA64323B1 (fr) | 2025-06-30 |
| HRP20250632T1 (hr) | 2025-07-18 |
| EP4609865A3 (en) | 2025-10-29 |
| IL307188A (en) | 2023-11-01 |
| MX2023012907A (es) | 2023-11-08 |
| RS66893B1 (sr) | 2025-07-31 |
| FI4337652T3 (fi) | 2025-06-20 |
| KR20240007152A (ko) | 2024-01-16 |
| WO2022238347A1 (en) | 2022-11-17 |
| PL4337652T3 (pl) | 2025-07-14 |
| CR20230529A (es) | 2023-12-04 |
| CO2023016204A2 (es) | 2023-12-11 |
| LT4337652T (lt) | 2025-06-25 |
| ES3031704T3 (en) | 2025-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR125818A1 (es) | Inhibidores de nlrp3 | |
| AR126053A1 (es) | Derivados de triazina | |
| CL2022001091A1 (es) | Dihidrobenzofurano e inden analogos como inhibidores de sarcómero cardíaco (divisional de solicitud 202001871). | |
| AR127705A1 (es) | Heterociclos inhibidores de nlrp3 | |
| CO2024001367A2 (es) | Compuestos antivirales | |
| AR115822A1 (es) | Compuestos de sulfonimidamida como inhibidores de la actividad de interleuquina-1 | |
| PE20220705A1 (es) | Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin y compuestos relacionados como inhibidores de proteina bcl-xl y agentes proapoptoticos para el tratamiento del cancer | |
| AR127704A1 (es) | Derivados de piridazina inhibidores de nlrp3 | |
| AR132295A1 (es) | Inhibidores de kras | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR132294A1 (es) | Inhibidores de kras | |
| CO6190582A2 (es) | Derivados de heteroarilamida | |
| PE20020131A1 (es) | Derivados de pirazol | |
| AR043111A1 (es) | Derivados monoacilados de o-fenilendiaminas | |
| PE20212253A1 (es) | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd) | |
| CL2023002616A1 (es) | Inhibidores del sarcómero cardíaco | |
| PE20242071A1 (es) | Compuestos moduladores de diacilglicerol quinasa | |
| CU20210023A7 (es) | Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4 | |
| AR090557A1 (es) | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 | |
| CL2017000839A1 (es) | Espiroindolinas para el tratamiento y profilaxis de infección por virus respiratorio sincitial (rsv) | |
| MX2019008331A (es) | Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos. | |
| PE20241894A1 (es) | Inhibidores de parp7 | |
| AR121999A1 (es) | Síntesis de intermedios para inhibidores de mcl-1 macrocíclicos mediante un cierre de anillo | |
| CL2021003139A1 (es) | Compuestos tricíclicos | |
| PE20040365A1 (es) | Inhibidores de la transcriptasa inversa no nucleosidos |